查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1974300

獸用抗生素市場：按類別、動物類型、最終用戶和治療領域分類－全球預測，2026-2032年

Veterinary Antibiotics Market by Class, Animal Type, End-User, Therapeutic Areas - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，獸用抗生素市場價值將達到 53.2 億美元，到 2026 年將成長至 55.9 億美元，到 2032 年將達到 78.8 億美元，複合年成長率為 5.76%。

主要市場統計數據
基準年 2025 53.2億美元
預計年份：2026年 55.9億美元
預測年份：2032年 78.8億美元
複合年成長率 (%) 5.76%

獸醫抗生素趨勢的背景框架，強調臨床方面、監管方面、供應鏈和合理使用抗生素的交匯點塑造了當今的治療環境。

獸用抗生素領域在動物健康、食品安全和合理使用抗菌藥物方面發揮著至關重要的作用。臨床趨勢、不斷演變的法規結構以及公共衛生部門日益嚴格的監管正在重塑伴侶動物和家畜抗生素的選擇、使用和監測方式。臨床醫生和生產者都面臨著相互衝突的壓力：既要保持療效，又要控制藥物殘留和抗藥性，還要在不斷變化的生物安全要求下確保家畜健康。

該評估評估了美國在 2025 年實施的關稅調整對各相關人員在供應鏈區域化、庫存策略改變和待遇選擇轉變方面所發揮的催化作用。

美國2025年生效的關稅政策變化對獸用抗生素供應鏈產生了多方面的影響，波及生產商、經銷商和終端用戶。部分進口商品關稅的提高迫使企業重新思考籌資策略，加速投資本地產能，轉向關稅區外的替代供應商。雖然這種籌資策略的轉變增強了部分相關人員的策略韌性，但也迫使其他利害關係人承擔過渡成本，並重新認證相關人員以符合獸藥品質標準。

為了促進策略優先排序和管理政策的製定，透過綜合細分分析，整合藥物類別、動物類型、最終用戶管道和治療適應症，可以獲得深刻見解。

細分分析揭示了影響臨床實踐和商業性重點的關鍵治療領域、類型和最終用戶差異。

關於對美洲、歐洲、中東和非洲以及亞太地區區域策略的影響，我們將重點放在影響抗生素使用的監管、生產和控制方面的差異。

區域趨勢持續對全球獸用抗生素的供應、監管和臨床實踐產生決定性影響。在美洲，監管力度加大和消費者期望的提高推動了更透明的合理用藥報告和診斷技術的應用。同時，供應鏈正朝著本地化方向發展，以減少對長途進口的依賴。在歐洲、中東和非洲，法規環境日益多元化，歐洲部分地區實施了嚴格的使用限制和監測計劃，而中東和非洲則優先考慮獲取途徑、能力建設和基礎設施發展，以支持合理使用抗生素。在亞太地區，生產能力和製造技術正在快速發展，但各國監管成熟度的差異正在影響出口模式和本地供應。

主要參與企業之間的競爭定位和營運模式表明，投資組合重點、區域夥伴關係和管理一致性決定了其在行業內的影響力。

主要企業的趨勢揭示了領導力、產品系列廣度和策略投資如何塑造其在獸用抗生素領域的競爭地位。成熟的動物用藥品公司持續利用其整合的研發能力、廣泛的產品註冊和完善的分銷網路，以維持其在伴侶動物和家畜領域的市場地位。它們的策略重點通常是對給藥系統和診斷技術的選擇性投資，以增強治療效果和用藥依從性，同時在現有藥物的生命週期管理與漸進式創新之間取得平衡。

為領導者提供可操作的優先建議，重點在於供應鏈韌性、綜合管理解決方案和產品組合最佳化，以應對監管和臨床挑戰。

產業領導者應採取的實際步驟可歸納為三個相互依存的優先事項：增強供應鏈韌性、透過診斷技術和教育促進資源管理，以及最佳化產品和組合策略以反映臨床實際情況和監管要求。增強供應鏈韌性需要採取策略性方法，實現供應商多元化，投資區域性製造地或合格的夥伴關係，並加強庫存管理方法，以確保醫療保健服務的連續性，同時降低貿易中斷帶來的風險。

我們採用了高度透明的混合調查方法，結合了初步訪談、文獻整合、監管審查、檢驗和情境分析，以支持我們的研究結果。

本調查方法結合了定性和定量技術，以確保研究的透明度和可重複性，同時產生可靠的實踐見解。初步調查包括對獸醫、法規專家、生產設施經理和分銷主管進行結構化訪談，以收集他們對製劑行為、採購挑戰和法規遵從性的直接意見。為了補充這些訪談，我們也進行了同儕審查文獻回顧，並系統地檢驗了法規指導文件、產品標籤和藥物監測記錄，以確保臨床和法規資訊的準確性。

整合策略洞察：透過協作管理、供應鏈韌性和務實的臨床協調來維持獸用抗生素的有效性

總之，獸用抗生素生態系統正走在一條由監管調整、供應鏈重組以及對藥物管理和診斷日益重視相關人員驅動的轉型之路上。積極主動進行調整的利害關係人——例如投資於具有韌性的供應鏈、透過診斷技術開展合作以推動藥物配方研發，以及調整產品策略以適應當地實際情況和治療需求——將更有能力應對監管審查和不斷變化的臨床預期。這些調整的累積效應將建構一個更課責、數據驅動的治療環境，在優先考慮動物健康結果的同時，保護公眾健康利益。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 獸用抗生素市場：依類別分類

  • Aminoglycosides
    • Amikacin
    • 阿普拉黴素
    • 慶大霉素
    • 卡那黴素
    • 新黴素
  • 氨苯醇
    • 阿齊達姆苯酚
    • 蘭姆酒
    • 氟苯尼考
    • 甲硫黴素
    • 噻吩酚
  • 頭孢菌素
    • 頭孢氨芐
    • 頭狀花序
    • Cefazolin
    • 頭孢維星
    • 塞夫蒂奧弗魯
    • 頭孢曲松
  • Fluoroquinolones
    • 達諾沙星
    • 地氟沙星
    • 恩諾沙星
    • 諾氟沙星
    • 奧比沙星
  • 大環內酯類
    • 阿奇黴素
    • 克拉黴素
    • 紅黴素
    • 加米麴黴素
    • 螺旋黴素
    • 奇爾米考辛
    • 圖拉黴素
    • 泰樂菌素
  • 其他奎諾酮抗生素
    • 辛諾沙星
    • 萘利酸
    • 奧索利酸
    • 哌咪酸
    • 羅沙沙星
  • 青黴素類
    • 阿莫西林
    • Ampicillin
    • 氯唑西林
    • 苯唑西林
    • 青黴素G
    • 青黴素V
  • 多粘菌素
    • 粘菌素/多粘菌素E
    • 多粘菌素B
  • 磺胺類藥物
    • 磺胺嘧啶
    • 磺胺嘧啶
    • 磺胺甲噻唑
    • 磺胺甲噁唑
    • 柳氮磺胺吡啶
  • 四環黴素
    • 四環黴素
    • 多西環素
    • 四環黴素
    • 四環黴素
  • 甲氧芐啶系統
    • 複方磺胺甲組合藥物
    • 甲氧芐啶磺胺嘧啶
    • 甲氧芐啶磺胺
    • 甲氧芐啶磺胺多辛
    • 複方磺胺甲噁唑（TMP-SMX）

第9章 獸用抗生素市場：依動物類型分類

  • 伴侶動物
    • 貓
    • 狗
  • 農場動物
    • 牛
    • 家禽
    • 綿羊/山羊
    • 豬

第10章 獸用抗生素市場：依最終用戶分類

  • 畜牧設施
  • 家庭中的寵物主人
  • 動物醫院

第11章 獸用抗生素市場：依治療領域分類

  • 皮膚感染疾病
  • 胃腸道感染疾病
  • 生殖系統感染疾病
  • 呼吸道感染疾病
  • 軟組織與傷口感染疾病
  • 全身性行為感染
  • 尿道感染

第12章 獸用抗生素市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 獸用抗生素市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 獸用抗生素市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國獸用抗生素市場

第16章：中國獸用抗生素市場

第17章：巴基斯坦獸用抗生素市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Ashish Life Science Private Limited
  • Bimeda Inc.
  • Biogenesis Bago SA
  • CH Boehringer Sohn AG & Co. KG
  • Ceva Sante Animale
  • Dechra Pharmaceuticals PLC
  • Eco Animal Health Group PLC
  • Elanco Animal Health Incorporated
  • Intas Pharmaceuticals Ltd.
  • Krka, dd, Novo mesto
  • Kyoritsuseiyaku Corporation
  • LABORATORIO AVI-MEX
  • LABORATORIOS CALIER, SA
  • Merck KGaA
  • Neogen Corporation
  • Ourofino Group
  • Sequent Scientific Ltd.
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-1B650A78937F

The Veterinary Antibiotics Market was valued at USD 5.32 billion in 2025 and is projected to grow to USD 5.59 billion in 2026, with a CAGR of 5.76%, reaching USD 7.88 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.32 billion
Estimated Year [2026] USD 5.59 billion
Forecast Year [2032] USD 7.88 billion
CAGR (%) 5.76%

Contextual framing of veterinary antibiotic dynamics highlighting clinical, regulatory, supply chain, and stewardship intersections shaping today's therapeutic landscape

The veterinary antibiotics landscape occupies a pivotal role at the intersection of animal health, food safety, and antimicrobial stewardship. Trends in clinical practice, evolving regulatory frameworks, and heightened scrutiny from public health authorities have collectively reshaped how antibiotics are selected, administered, and monitored across companion animals and livestock. Clinicians and producers alike are navigating competing pressures: the need to preserve therapeutic efficacy, the imperative to limit residues and resistance, and the operational demands of maintaining herd and flock health under changing biosecurity expectations.

In parallel, advances in pharmacology, diagnostics, and drug delivery are altering the therapeutic toolbox available to veterinarians. Rapid diagnostic tests and point-of-care tools are increasingly informing treatment decisions, enabling targeted therapy and shorter treatment courses when appropriate. Moreover, supply chain resiliency has become a strategic consideration as manufacturers, distributors, and end-users adapt to disruptions and implement redundancies that prioritize continuity of care.

This introduction situates the reader within a dynamic ecosystem in which clinical best practices, regulatory enforcement, and commercial strategies converge. It underscores the necessity for stakeholders to make evidence-based decisions that prioritize both animal welfare and public health, and it sets the stage for examining the consequential shifts, segmentation nuances, regional distinctions, and actionable steps that follow in the report.

The veterinary antibiotics sector has been transformed by several concurrent forces that are reconfiguring clinical paradigms, supply relationships, and regulatory oversight. Regulatory changes and heightened enforcement have driven tighter controls on use patterns, prompting both manufacturers and clinicians to rethink label indications, withdrawal periods, and off-label practices. These regulatory pressures have accelerated innovation in diagnostic tools and stewardship programs that prioritize judicious antibiotic use while incentivizing alternative measures such as vaccination, biosecurity, and management improvements.

Supply chain and sourcing dynamics have undergone a strategic reorientation as companies seek greater resilience. Manufacturers diversified supplier bases and regionalized production to mitigate geopolitical and transportation risks, and distributors increasingly emphasize inventory visibility and cold-chain integrity. These operational adjustments have improved continuity of supply for critical antibiotics but have also introduced complexity in procurement, compliance, and cost management. Concurrently, R&D priorities have shifted to focus not only on novel compounds but on formulations that facilitate targeted delivery, reduced dosing frequency, and minimized residue risk.

Market expectations have evolved alongside scientific and regulatory trends. End-users now demand greater transparency on antibiotic stewardship outcomes and traceability across product lifecycles. Veterinary practitioners are adopting evidence-driven prescribing supported by rapid diagnostics and enhanced data capture, which together enable outcome-based decisions and better antimicrobial usage monitoring. Collectively, these transformative shifts are producing a more accountable, data-rich, and strategically oriented antibiotics ecosystem in veterinary medicine.

Assessment of how 2025 United States tariff adjustments functioned as a catalyst for supply chain localization, inventory strategy changes, and therapeutic selection shifts across stakeholders

United States tariff policy changes that became noticeable in 2025 exert a multifaceted influence on the veterinary antibiotics supply chain, with effects that ripple across manufacturers, distributors, and end-users. Elevated tariffs on selected imports prompted firms to reassess sourcing strategies, accelerating investments in local production capabilities and alternative suppliers located outside tariff-impacted corridors. This sourcing pivot has improved strategic resilience for some stakeholders but has required others to absorb transition costs and requalify suppliers to meet veterinary pharmaceutical quality standards.

The tariff environment also accelerated the reconfiguration of trade routes and logistics practices. Importers and distributors responded by building longer lead times into procurement planning and by increasing reliance on regional warehouses to reduce exposure to tariff-related disruptions. In many cases, this led to a rebalancing of inventory practices toward higher safety stock for critical antibiotic families to prevent treatment interruptions. Veterinary service providers and producers responded by prioritizing antibiotics with stable supply profiles or by integrating non-antibiotic disease prevention approaches such as enhanced vaccination and improved husbandry practices.

Policy-driven cost pressures intensified conversations around product selection, formulary design, and stewardship prioritization. Given these dynamics, companies realigned commercial strategies to emphasize product portfolios that benefit from local manufacturing scalability, regulatory clarity, and traceability. Although tariffs were not the sole catalyst for change, they acted as a forcing function that accelerated decisions around supply chain localization, contract adjustments, and investment in alternative therapeutic and preventive measures across the veterinary ecosystem.

Comprehensive segmentation-driven insight synthesizing drug classes, animal types, end-user channels, and therapeutic indications to inform strategic prioritization and stewardship

Segmentation analysis reveals important therapeutic, species-specific, and end-user distinctions that shape clinical practice and commercial focus. The product class structure encompasses Aminoglycosides, Amphenicols, Cephalosporins, Fluoroquinolones, Macrolides, Other Quinolones, Penicillins, Polymixins, Sulfonamides, Tetracyclines, and Trimethoprim, with subcategories that include drugs such as Amikacin, Apramycin, Gentamicin, Kanamycin, Neomycin, Azidamfenicol, Chloramphenicol, Florfenicol, Metiamycin, Thiamphenicol, Cefalexin, Cefalonium, Cefazolin, Cefovecin, Ceftiofur, Ceftriaxone, Ciprofloxacin, Danofloxacin, Difloxacin, Enrofloxacin, Norfloxacin, Orbifloxacin, Azithromycin, Clarithromycin, Erythromycin, Gamithromycin, Spiramycin, Tilmicosin, Tulathromycin, Tylosin, Cinoxacin, Nalidixic Acid, Oxolinic Acid, Pipemidic Acid, Rosoxacin, Amoxicillin, Ampicillin, Cloxacillin, Oxacillin, Penicillin G, Penicillin V, Colistin/Polymyxin E, Polymyxin B, Sulfadiazine, Sulfamerazine, Sulfamethizole, Sulfamethoxazole, Sulfasalazine, Chlortetracycline, Doxycycline, Oxytetracycline, Tetracycline, and combinations involving Trimethoprim plus various sulfonamides including TMP-SMX.

Animal type delineation clarifies where demand and clinical practice diverge. Companion animals and livestock are examined with companion animals further characterized by cats and dogs, and livestock further divided into cattle, poultry, sheep and goats, and swine. End-user segmentation distinguishes animal production facilities, household pet owners, and veterinary clinics as primary channels through which antibiotics are accessed and administered, each with distinct procurement, storage, and stewardship practices. Therapeutic area segmentation highlights common intervention points including dermatological infections, gastrointestinal infections, reproductive system infections, respiratory infections, soft tissue and wound infections, systemic infections, and urinary tract infections, which together inform formulary development and prescribing protocols.

Understanding these segmentations in combination is crucial for aligning product development, distribution strategies, and stewardship initiatives. For example, certain classes such as macrolides and tetracyclines are often prioritized in respiratory and systemic indications in livestock, while specific cephalosporins and penicillins remain central to companion animal practice. Differences in end-user procurement behaviors, whether institutional purchasing at animal production facilities or retail and clinic-based access for pet owners, create distinct commercial pathways for manufacturers and distributors to navigate.

Regional strategy implications across Americas, Europe Middle East & Africa, and Asia-Pacific highlighting regulatory, production, and stewardship differentials affecting antibiotic usage

Regional dynamics continue to exert a determining influence on supply, regulation, and clinical practice in veterinary antibiotics across the globe. In the Americas, regulatory scrutiny and consumer expectations have driven more transparent stewardship reporting and increased adoption of diagnostics, while supply chains have leaned toward regionalization to reduce dependence on long-distance imports. Europe, Middle East & Africa present a heterogeneous regulatory tapestry, with parts of Europe enforcing stringent use restrictions and monitoring programs, and regions within the Middle East and Africa prioritizing access, capacity building, and infrastructure improvements to support appropriate antibiotic use. The Asia-Pacific region demonstrates rapid shifts in production capacity and manufacturing sophistication, combined with diverse regulatory maturity across countries that shapes export patterns and local availability.

These regional contrasts affect product lifecycle decisions and operational priorities. Companies evaluating formulation portfolios and registration investments must reconcile regional regulatory expectations with distribution channel realities. For instance, formulations that meet residue and withdrawal expectations in one jurisdiction may require additional studies or different labeling to comply elsewhere. Moreover, regional disease profiles and livestock production systems influence antibiotic selection; production systems in certain regions favor particular classes or administration routes due to management practices, climatic conditions, and prevailing pathogens.

Strategic actors therefore allocate resources based on regional priorities: investing in local manufacturing where supply security is a business imperative, enhancing regulatory affairs capabilities to navigate complex approvals, and tailoring stewardship communications to resonate with regional veterinary and producer communities. These region-specific strategies support both short-term operational continuity and long-term market access objectives.

Competitive positioning and operational patterns among leading players showing how portfolio focus, regional partnerships, and stewardship alignment determine industry influence

Key company dynamics reveal how leadership, portfolio breadth, and strategic investments shape competitive positioning within the veterinary antibiotics domain. Established animal health companies continue to leverage integrated research and development capabilities, broad product registries, and expansive distribution networks to sustain presence across both companion animal and livestock segments. Their strategic focus often balances incremental innovation with lifecycle management of legacy molecules, while investing selectively in delivery systems and diagnostics that enhance therapeutic outcomes and stewardship compliance.

Mid-sized and specialty players focus on niche therapeutic classes, regionally optimized formulations, or service-led models that pair products with diagnostic and advisory services. These firms frequently adopt agile commercialization approaches, pursuing targeted regulatory filings and partnerships to expand geographic reach without replicating the capital intensity of global manufacturing. Contract manufacturing organizations and regional distributors play an outsized role in ensuring product availability, enabling manufacturers to scale presence through strategic alliances.

Across the competitive landscape, successful companies demonstrate an ability to align stewardship messaging with commercial objectives, invest in supply chain transparency, and collaborate with veterinary associations, producers, and regulators to support responsible use. This alignment not only mitigates regulatory and reputational risk but also fosters trust with clinicians and producers who increasingly evaluate suppliers based on quality, traceability, and ethical practices.

Actionable priority recommendations for leaders focusing on supply resilience, integrated stewardship solutions, and portfolio optimization to navigate regulatory and clinical challenges

Actionable steps for industry leaders coalesce around three interdependent priorities: strengthening supply resilience, advancing stewardship through diagnostics and education, and optimizing product and portfolio strategies to reflect clinical realities and regulatory expectations. Strengthening supply resilience requires a strategic approach to supplier diversification, investment in regional manufacturing or qualified partnerships, and enhanced inventory management practices that reduce vulnerability to trade disruptions while ensuring continuity of care.

Advancing stewardship entails integrating rapid diagnostics, data capture, and clinician education into commercial offerings so that prescribing decisions are supported by timely information and outcome monitoring. Companies should proactively partner with veterinary associations, producers, and policy makers to design stewardship frameworks that balance access with preservation of antibiotic efficacy. This collaborative approach reinforces trust and positions firms as constructive participants in public health objectives.

Optimizing product and portfolio strategies means prioritizing formulations and indications that align with regional disease burdens, withdrawal requirements, and end-user workflows. Manufacturers should consider flexible regulatory pathways and modular registration strategies to accelerate access across jurisdictions. Additionally, embedding service elements-such as diagnostic support, training modules, and tailored stewardship materials-creates differentiation and supports sustainable demand for products within evolving clinical and regulatory environments.

Transparent, mixed-methods research approach blending primary interviews, literature synthesis, regulatory review, triangulation, and scenario analysis to underpin findings

The research methodology combines qualitative and quantitative techniques designed to produce robust, actionable insights while ensuring transparency and repeatability. Primary research included structured interviews with veterinarians, regulatory experts, production facility managers, and distribution executives to capture first-hand perspectives on prescribing behavior, procurement challenges, and regulatory compliance. These interviews were complemented by peer-reviewed literature reviews and a systematic examination of regulatory guidance documents, product labeling, and pharmacovigilance records to ensure clinical and regulatory accuracy.

Secondary research incorporated publicly available technical papers, clinical guidelines, and industry white papers to contextualize primary findings within broader scientific and policy trends. Data triangulation methods were employed to reconcile differing viewpoints and validate thematic conclusions, ensuring that strategic recommendations rest on convergent evidence. The approach also included scenario analysis to explore operational implications of policy shifts and supply chain disruptions, and sensitivity checks to test the robustness of qualitative inferences under alternative assumptions.

Ethical considerations and data governance protocols were observed throughout, ensuring interviewee confidentiality and adherence to relevant data protection norms. The methodology is transparent about its limitations, acknowledging areas where evidence is emerging and where further targeted research or clinical studies could strengthen causal understanding.

Synthesis of strategic implications highlighting collaborative stewardship, supply chain resilience, and pragmatic clinical alignment to sustain veterinary antibiotic efficacy

In conclusion, the veterinary antibiotics ecosystem is in the midst of purposeful change driven by regulatory realignment, supply chain recalibration, and a growing emphasis on stewardship and diagnostics. Stakeholders who proactively adapt-by investing in resilient supply chains, partnering to advance diagnostic-driven prescribing, and aligning product strategies with regional and therapeutic realities-are positioned to navigate both regulatory scrutiny and shifting clinical expectations. The cumulative effect of these adjustments is a more accountable and data-informed therapeutic environment that prioritizes animal health outcomes while safeguarding public health interests.

While challenges remain, particularly around harmonizing regulations across regions and ensuring equitable access to quality antibiotics, the path forward is defined by collaboration among manufacturers, clinicians, regulators, and producers. Shared commitments to transparency, evidence-driven prescribing, and investment in alternatives to routine antibiotic use will shape the sector's sustainability. The insights presented here are intended to inform strategy, guide tactical decisions, and stimulate constructive dialogue toward responsible antibiotic stewardship across the veterinary continuum.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Veterinary Antibiotics Market, by Class

  • 8.1. Aminoglycosides
    • 8.1.1. Amikacin
    • 8.1.2. Apramycin
    • 8.1.3. Gentamicin
    • 8.1.4. Kanamycin
    • 8.1.5. Neomycin
  • 8.2. Amphenicols
    • 8.2.1. Azidamfenicol
    • 8.2.2. Chloramphenicol
    • 8.2.3. Florfenicol
    • 8.2.4. Metiamycin
    • 8.2.5. Thiamphenicol
  • 8.3. Cephalosporins
    • 8.3.1. Cefalexin
    • 8.3.2. Cefalonium
    • 8.3.3. Cefazolin
    • 8.3.4. Cefovecin
    • 8.3.5. Ceftiofur
    • 8.3.6. Ceftriaxone
  • 8.4. Fluoroquinolones
    • 8.4.1. Danofloxacin
    • 8.4.2. Difloxacin
    • 8.4.3. Enrofloxacin
    • 8.4.4. Norfloxacin
    • 8.4.5. Orbifloxacin
  • 8.5. Macrolides
    • 8.5.1. Azithromycin
    • 8.5.2. Clarithromycin
    • 8.5.3. Erythromycin
    • 8.5.4. Gamithromycin
    • 8.5.5. Spiramycin
    • 8.5.6. Tilmicosin
    • 8.5.7. Tulathromycin
    • 8.5.8. Tylosin
  • 8.6. Other Quinolones
    • 8.6.1. Cinoxacin
    • 8.6.2. Nalidixic Acid
    • 8.6.3. Oxolinic Acid
    • 8.6.4. Pipemidic Acid
    • 8.6.5. Rosoxacin
  • 8.7. Penicillins
    • 8.7.1. Amoxicillin
    • 8.7.2. Ampicillin
    • 8.7.3. Cloxacillin
    • 8.7.4. Oxacillin
    • 8.7.5. Penicillin G
    • 8.7.6. Penicillin V
  • 8.8. Polymixins
    • 8.8.1. Colistin/Polymyxin E
    • 8.8.2. Polymyxin B
  • 8.9. Sulfonamides
    • 8.9.1. Sulfadiazine
    • 8.9.2. Sulfamerazine
    • 8.9.3. Sulfamethizole
    • 8.9.4. Sulfamethoxazole
    • 8.9.5. Sulfasalazine
  • 8.10. Tetracyclines
    • 8.10.1. Chlortetracycline
    • 8.10.2. Doxycycline
    • 8.10.3. Oxytetracycline
    • 8.10.4. Tetracycline
  • 8.11. Trimethoprim
    • 8.11.1. Trimethoprim Plus Sulfamethazine
    • 8.11.2. Trimethoprim-Sulfadiazine
    • 8.11.3. Trimethoprim-Sulfadimidine
    • 8.11.4. Trimethoprim-Sulfadoxine
    • 8.11.5. Trimethoprim-Sulfamethoxazole (TMP-SMX)

9. Veterinary Antibiotics Market, by Animal Type

  • 9.1. Companion Animals
    • 9.1.1. Cats
    • 9.1.2. Dogs
  • 9.2. Livestock
    • 9.2.1. Cattle
    • 9.2.2. Poultry
    • 9.2.3. Sheep & Goats
    • 9.2.4. Swine

10. Veterinary Antibiotics Market, by End-User

  • 10.1. Animal Production Facilities
  • 10.2. Household Pet Owners
  • 10.3. Veterinary Clinics

11. Veterinary Antibiotics Market, by Therapeutic Areas

  • 11.1. Dermatological Infections
  • 11.2. Gastrointestinal Infections
  • 11.3. Reproductive System Infections
  • 11.4. Respiratory Infections
  • 11.5. Soft Tissue & Wound Infections
  • 11.6. Systemic Infections
  • 11.7. Urinary Tract Infections

12. Veterinary Antibiotics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Veterinary Antibiotics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Veterinary Antibiotics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Veterinary Antibiotics Market

16. China Veterinary Antibiotics Market

17. Pakistan Veterinary Antibiotics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Ashish Life Science Private Limited
  • 18.6. Bimeda Inc.
  • 18.7. Biogenesis Bago S.A.
  • 18.8. C.H. Boehringer Sohn AG & Co. KG
  • 18.9. Ceva Sante Animale
  • 18.10. Dechra Pharmaceuticals PLC
  • 18.11. Eco Animal Health Group PLC
  • 18.12. Elanco Animal Health Incorporated
  • 18.13. Intas Pharmaceuticals Ltd.
  • 18.14. Krka, d. d., Novo mesto
  • 18.15. Kyoritsuseiyaku Corporation
  • 18.16. LABORATORIO AVI-MEX
  • 18.17. LABORATORIOS CALIER, S.A.
  • 18.18. Merck KGaA
  • 18.19. Neogen Corporation
  • 18.20. Ourofino Group
  • 18.21. Sequent Scientific Ltd.
  • 18.22. Vetoquinol SA
  • 18.23. Virbac SA
  • 18.24. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VETERINARY ANTIBIOTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VETERINARY ANTIBIOTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA VETERINARY ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. PAKISTAN VETERINARY ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMIKACIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMIKACIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMIKACIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY APRAMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY APRAMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY APRAMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY GENTAMICIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY GENTAMICIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY GENTAMICIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY KANAMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY KANAMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY KANAMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY NEOMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY NEOMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY NEOMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AZIDAMFENICOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AZIDAMFENICOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AZIDAMFENICOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CHLORAMPHENICOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CHLORAMPHENICOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CHLORAMPHENICOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY FLORFENICOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY FLORFENICOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY FLORFENICOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY METIAMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY METIAMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY METIAMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY THIAMPHENICOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY THIAMPHENICOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY THIAMPHENICOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFALEXIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFALEXIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFALEXIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFALONIUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFALONIUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFALONIUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFAZOLIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFAZOLIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFAZOLIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFOVECIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFOVECIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFOVECIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFTIOFUR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFTIOFUR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFTIOFUR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFTRIAXONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFTRIAXONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFTRIAXONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DANOFLOXACIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DANOFLOXACIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DANOFLOXACIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DIFLOXACIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DIFLOXACIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DIFLOXACIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ENROFLOXACIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ENROFLOXACIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ENROFLOXACIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY NORFLOXACIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY NORFLOXACIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY NORFLOXACIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ORBIFLOXACIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ORBIFLOXACIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ORBIFLOXACIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AZITHROMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AZITHROMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AZITHROMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CLARITHROMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CLARITHROMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CLARITHROMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ERYTHROMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ERYTHROMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ERYTHROMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY GAMITHROMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY GAMITHROMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY GAMITHROMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SPIRAMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SPIRAMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SPIRAMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TILMICOSIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TILMICOSIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TILMICOSIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TULATHROMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TULATHROMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TULATHROMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TYLOSIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TYLOSIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TYLOSIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CINOXACIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CINOXACIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CINOXACIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY NALIDIXIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY NALIDIXIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY NALIDIXIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY OXOLINIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY OXOLINIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY OXOLINIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY PIPEMIDIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY PIPEMIDIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY PIPEMIDIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ROSOXACIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ROSOXACIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ROSOXACIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMOXICILLIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMOXICILLIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMOXICILLIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPICILLIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPICILLIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPICILLIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CLOXACILLIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CLOXACILLIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CLOXACILLIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY OXACILLIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY OXACILLIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY OXACILLIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLIN G, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLIN G, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLIN G, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLIN V, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLIN V, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLIN V, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY COLISTIN/POLYMYXIN E, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY COLISTIN/POLYMYXIN E, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY COLISTIN/POLYMYXIN E, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMYXIN B, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMYXIN B, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMYXIN B, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFADIAZINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFADIAZINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFADIAZINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFAMERAZINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFAMERAZINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFAMERAZINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFAMETHIZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFAMETHIZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFAMETHIZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFAMETHOXAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFAMETHOXAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFAMETHOXAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFASALAZINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFASALAZINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFASALAZINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CHLORTETRACYCLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CHLORTETRACYCLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CHLORTETRACYCLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DOXYCYCLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DOXYCYCLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DOXYCYCLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY OXYTETRACYCLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY OXYTETRACYCLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY OXYTETRACYCLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM PLUS SULFAMETHAZINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM PLUS SULFAMETHAZINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM PLUS SULFAMETHAZINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM-SULFADIAZINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM-SULFADIAZINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM-SULFADIAZINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM-SULFADIMIDINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM-SULFADIMIDINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM-SULFADIMIDINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM-SULFADOXINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM-SULFADOXINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM-SULFADOXINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM-SULFAMETHOXAZOLE (TMP-SMX), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM-SULFAMETHOXAZOLE (TMP-SMX), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM-SULFAMETHOXAZOLE (TMP-SMX), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 232. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY POULTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY POULTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 235. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SHEEP & GOATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SHEEP & GOATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 238. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SHEEP & GOATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SWINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SWINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 241. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 242. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL PRODUCTION FACILITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 244. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL PRODUCTION FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL PRODUCTION FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY HOUSEHOLD PET OWNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 247. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY HOUSEHOLD PET OWNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 248. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY HOUSEHOLD PET OWNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 250. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 251. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 253. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DERMATOLOGICAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 254. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DERMATOLOGICAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 255. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DERMATOLOGICAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 257. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 258. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY REPRODUCTIVE SYSTEM INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 260. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY REPRODUCTIVE SYSTEM INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 261. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY REPRODUCTIVE SYSTEM INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 263. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 264. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SOFT TISSUE & WOUND INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 266. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SOFT TISSUE & WOUND INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 267. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SOFT TISSUE & WOUND INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SYSTEMIC INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 269. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SYSTEMIC INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 270. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SYSTEMIC INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 272. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 273. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 275. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 276. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2018-2032 (USD MILLION)
  • TABLE 277. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 278. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, 2018-2032 (USD MILLION)
  • TABLE 279. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 280. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2032 (USD MILLION)
  • TABLE 281. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 282. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, 2018-2032 (USD MILLION)
  • TABLE 283. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 284. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, 2018-2032 (USD MILLION)
  • TABLE 285. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 286. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 287. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, 2018-2032 (USD MILLION)
  • TABLE 288. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 290. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 291. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 292. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA VETERINARY ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 294. NORTH AMERICA VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2018-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 296. NORTH AMERICA VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, 2018-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 298. NORTH AMERICA VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 300. NORTH AMERICA VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, 2018-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 302. NORTH AMERICA VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, 2018-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 304. NORTH AMERICA VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, 2018-2032 (USD MILLION)
  • TABLE 306. NORTH AMERICA VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 308. NORTH AMERICA VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 310. NORTH AMERICA VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (US